Industrial Biotechnology Innovation Centre Vision 2030

Industrial Biotechnology Innovation Centre Vision 2030 Vision Vision “Our vision is to create a truly distinctive world-leading Industrial Biotech...
17 downloads 1 Views 2MB Size
Industrial Biotechnology Innovation Centre Vision 2030

Vision

Vision

“Our vision is to create a truly distinctive world-leading Industrial Biotechnology Innovation Centre (IBioIC). We will accelerate and de-risk the development of commercially viable, sustainable solutions for high-value (speciality & commodity) manufacturing in chemistry-using and life science sectors. In so doing we will establish an innovation and growth engine yielding substantial economic impact and delivering increasing and sustainable wealth creation, prosperity and employment in Scotland. By 2030 our target is to generate 1.0 to 1.5 Billion pounds of Gross Value Added contribution annually to the Scottish economy, this represents a growth of revenue from today’s estimated value of £190M, to between £2 and 3bn”

01

Industrial Biotechnology Innovation Centre Vision 2030

Foreword

A

fter several false dawns biotechnology has emerged to be truly disruptive and transformational with substantial global impact. The acceleration of cost reduction in genome sequencing to its current level of halving every year is creating unforeseen and unpredictable opportunities. This Innovation Centre recognises the extensive intellectual, physical and natural resources that exist in Scotland and seeks to accelerate, catalyse and leverage the development and commercial exploitation through this highly distinctive capability. It will harness the combined intellectual horsepower of 13 Higher Education Institutes and create a single portal for industry to connect with. It will be staffed by true techno-commercial experts with the ability to identify opportunity, understand limitations and issues and provide viable and cost effective solution strategies that benefit both specific businesses and the overall Scottish Economy. Scotland already has a large

Ian Shott, CBE, FREng IBioIC Chairman

and diverse chemistry based industry and has global players covering a wide range of sectors from fuel, chemicals, polymers to pharmaceuticals, specialty effects, materials and food and drink. This is a multibillion pound per annum market and modern Industrial Biotechnology can have substantial impact on the whole spectrum of manufacturing. The Centre will respond to and support the needs of all types of businesses from start-ups to small medium enterprises and through to large companies and global multinationals. Apart from supporting indigenous players it will seek to attract foreign companies to invest in Scotland. IBioIC will operate at the cutting edge of new technology but our objective will be to help create robust and scalable technology that is commercially viable within the shortest possible development time. We are excited and proud to be part of this game changing endeavour and are committed to creating a sustainable and fast growing centre delivering substantial and increasing benefits in the short, medium and long term.

Professor Sir James McDonald, Principal and Vice-Chancellor, University of Strathclyde

Table of Contents Executive Summary

2

Key messages

4

Market Opportunities

5

Industrial membership

7

Operational Model 9 Academic partners 12 Implementation plan 13 Funding & Financial plan 15 Impact 16 Skills & Knowledge Exchange 17 Leadership, Management & Governance 18 Conclusions 20 Acknowledgements 22

02

Executive Summary

Executive Summary

T

raditionally, four ‘colours’ of biotechnology have been defined to represent the main origins and applications of the technology: white – industrial applications; red – human health and cell therapies; green – plant and agricultural and blue – marine materials and organisms.

The consortium of thirteen Scottish HEI partners, combined with the abundant natural resources within Scotland will uniquely encompass, in one distinctive IC, all four colours of IB and translate knowledge between them in order to gain maximum leverage and value and the best utilization of resources, regardless of origin.

Scotland’s HEIs have worldclass skills in research and Our industry partners have identified have core competences in five major themes for IBioIC many organisms used in IB. These include feedstock • Sustainable Feedstocks manipulation, systems and (including unconventional gases) synthetic biology, biocatalysis, • Enzymes and Biocatalysis / and applied research in Biotransformation areas directly relevant to the • Cell Factory Construction and exploitation of IB. On the back Process Physiology of these substantial resources • Downstream Processing and the already existing • Integrated Bioprocessing business base in Scotland we aim to get rapid traction and create a fertile environment for technology development spawning new companies as IBioIC’s Industrial and Higher Education Institute (HEI) well as expanding existing businesses and attracting new Partners have made the unequivocal commitment investments from companies of all sizes and character. to the establishment of IBioIC as a world-leading industrial biotechnology centre for commercialisation of economically viable, sustainable solutions for high-value IBioIC aims to surpass the targets set by Scotland’s recently announced National Plan for IB. HEIs have the manufacturing in the life science and chemistry-using combined process competence over a range of organisms, sectors. In so doing we will establish an innovation and encapsulating all of the traditional four colours of growth engine, yielding substantial economic impact biotechnology and can operate across the entire and delivering increasing and sustainable wealth integrated bioprocessing span (Figure 1). This unique creation, prosperity and employment in Scotland. combination means it is capable of moving exciting, but low technology readiness level (TRL) projects up into The UK’s chemicals industry is the sixth largest in the high TRL programs capable of generating significant the world and in Scotland this translates to it being economic impact (Figure 3). the second top exporter (£3.7bn per annum), whilst Scotland’s life sciences sector is one of the largest and The access to world class research organisations, strong fastest-growing in Europe. These are ideal foundations project leadership and a passion to deliver business for the establishment of the IBioIC driving Scotland relevant solutions via the push from early concept to viable to the forefront of a global transformational change process represents an unequalled opportunity for the IBioIC from a largely fossil fuel-based to a more balanced and to exploit national and global market opportunities. sustainable IB-inclusive economy. The IBioIC has been formed and was launched as an operating entity in January 2014 with the full and strong support of industrial companies ranging from startups to multinational corporations covering all four colours of IB. This is indicative of a powerful business need for the IBioIC. The expert team we develop will constantly focus on market trends and industry need to shape the portfolio of projects.

03

Industrial Biotechnology Innovation Centre Vision 2030

IBioIC PROCESS COVERAGE Figure 1 illustrates IBioIC’s coverage of the entire integrated bioprocessing span. IBioIC will have process-ready organism chassis and process competence for a range of sustainable feedstocks (including unconventional gases) and by combining the power of the HEI partners, will be able to leverage a large cassette of tools from ‘Omics’, Systems Biology and Synthetic Biology. Consequently, IBioIC will be able to transform exciting novel technology at low Technology Readiness Levels (TRL) up into high TRL outcomes – a multitude of new products and processes for many industry sectors.

Figure 1 Integrated IB Process Flowchart. Organism Chassis: yeasts e.g. S. cerevisiae, P. pastoris; bacteria e.g. E. coli, Clostridium, Streptomyces; algae; engineering ‘cell factory’

Feedstocks

Pre-treatment

Biomass (carbohydrate) Waste/recycle (mix) Unconventional Gases Hydrocarbon or CO2

Fermentation

DSP

Thermal Chemical Biological Mechanical

Bio trans

DSP

Products

OMICS

INDUSTRIAL BIOTECHNOLOGY

Diagnostics Med tech Stratified medicines etc

SYNTHETIC BIOLOGY

IB Petro Chemical tree Materials etc

GENOMICS, PROTEOMICS, METABOLOMICS SYSTEMS BIOLOGY

Biosciences

Chemistry Sciences

Computational Sciences

LIFE SCIENCES /PHYSICAL SCIENCES

Engineering

04

Key Messages

KEY MESSAGES BUSINESS

GOVERNMENT

Industrial Biotechnology is a disruptive technology that will radically revolutionise the landscape of the chemistry using and life science industries.

Industrial Biotechnology offers significant opportunities for Scotland’s industries and through greater collaboration we aim to capture a significant share of the global market, which is projected to grow up to £360bn by 2025 helping Chemical Sciences Scotland meet its ambitious exporting target of £4.5 billion by 2020.

Innovative use of IB in the development of new products, feedstocks and processes will grow your business and help make it more competitive by using less water, less energy, producing less waste, using renewable raw materials and more compact production pathways. We will play a key role in offering opportunities to engage companies alongside HEI’s and transforming the industry. We can support your transition into Industrial Biotechnology by helping you to understand the benefits and opportunities, overcome any barriers and make sure you’re in touch with the right people to guide you through the technology and its consequent translation and implementation in your business. We will also work with our Business partners to develop the skilled workforce necessary to drive this Industry forward.

It is forecast that IBioIC will generate ca 1,500 Full Time Equivalent additional jobs within its first 5 years of operation. Working collaboratively with industrial partners, HEI’s and government, we will support Scottish businesses and industries to embrace the opportunities presented by Industrial Biotechnology and support them to increase their combined contribution to IB turnover to £900 million by 2025. A transition towards a bio-economy with effective exploitation of Industrial Biotechnology supports the Scottish Governments ambitious low carbon objectives by creating more businesses using sustainable business practices.

HIGHER EDUCATION INSTITUTIONS We will facilitate industrial collaborations across Scotland, the UK, EU and globally, which are crucial in the development of an internationally recognised Scottish Industrial Biotechnology strategy. We expect to access substantial grant funding from Horizon 2020, through collaborative projects, and a combination of diverse grant funding bodies with specific company contributions. A workforce with the required skills is essential to delivering this strategy. Therefore we will launch new industrial apprenticeships and a planned HND programme via appropriate Further Education Institutes with an MSc programme and supported PhD’s in IB through the HEI partners. To deliver the innovation required to bring about these Industrial changes we will promote and launch research programmes to deliver needed industrial solutions to accelerate the commercialisation of IB. We will capitalise on the strength of Scotland’s chemical and life sciences sectors initially, to drive industrial biotechnology activities.

05

Industrial Biotechnology Innovation Centre Vision 2030

NATIONAL AND GLOBAL MARKET OPPORTUNITIES The Industrial Biotechnology (IB) Innovation and Growth Team report: “IB 2025 Maximizing UK Opportunities from Industrial Biotechnology in a Low Carbon Economy” (BERR, 2009) recognized that “it is vital that the UK become more proactive in its takeup of IB” to maintain its competitiveness in global markets where bio-based systems and processes are rapidly gaining strength and scale. Consequently, the UK Government, through the Industrial Biotechnology Leadership Forum (IBLF), has outlined the following commercial and industry led objectives targeting to add £10 billion to the UK economy by 2025: • The UK will become a leading centre of competence in fine and specialty chemicals delivered via IB processes • There will be an increased uptake of bio-catalysis and fermentation in the existing UK chemical industry • The UK will become a top three producer of high value chemicals from plants • The UK will be recognised globally as a leading source of know-how in producing commodity and intermediate chemicals through bio-catalysis and fermentation. Great progress has been achieved with £2.3 billion already added to the UK economy, however significant challenges remain, including process intensification (achieving higher titres or process concentration with shorter cycle times) and shorter development cycles. The recent advances in genomics (the tumbling cost of gene sequencing now beating Moore’s Law) will be game changing and if combined with a diverse range of organism chassis and excellent translation and industrialisation technologies, will result in explosive growth. Scotland has demonstrable strengths in this landscape and the impetus to participate is reflected in Scotland’s National Plan for IB which aims to raise the estimated turnover of IB related products from £190m to £900m, or 10% of the chemical sciences sector’s related turnover, by 2025. Through IBioIC, this target will be surpassed. IBioIC’s Business Plan has been prepared in consultation with Chemical Sciences Scotland (CSS) and the strategy to establish IBioIC has been endorsed by Life Sciences Advisory Board (LiSAB). CSS identifies IB as a “transformational opportunity” as it can play a major role in achieving the objectives within its three themes of exports; low carbon and collaborations. Additionally, the Strategy for Life Sciences in Scotland recognises the value of the application of life sciences beyond healthcare including environmental remediation, the transformation of waste as a resource and consequent biofuel and higher value product manufacture. Furthermore, CSS and the Energy Advisory Board (EAB) are specifically looking at biofuels opportunities for Scotland through its Scottish Biofuels Task Force. IBioIC also has discussions underway with the Food and Drink, Forestry and Textiles sectors and all these activities will contribute to Scottish Enterprise, Highlands and Islands Enterprise and Scottish Government strategies for exports, low carbon economics, sustainability and innovation. continued on page 6 >>

“..Scotland, with its excellence in industrial biotechnology and with its remarkable resources and diversity in both its rural and coastal economies, is exceptionally well placed to play a leading role in helping to drive the creation of a robust and competitive EU bioeconomy” Joanna Dupont-Inglis, EuropaBio

“..I fully support the initiative to found this Scottish IBioIC and believe it will strengthen Scotland’s competitiveness in the global arena” Brent Erickson, BIO

06

National and Global Market Opportunities

NATIONAL AND GLOBAL MARKET OPPORTUNITIES The IBioIC will focus the rapidly developing technologies, such as synthetic biology, the increasing suite of “omics” and metrology, on the huge chemical and chemical using industries rather than the less commercially advanced applications in stratified medicine, diagnostics and personalized therapy. This strategy allows much more rapid value harvesting as it is built on a large, established industrial network as summarized in the Figure 2. Over the last five years, significant progress has been made on developing new IB process technologies for industries such as: pharmaceuticals (GSK, Fuji Diosynth, Ingenza), Cosmetics (Croda), Flavours (Oxford Chemicals), Platform Chemicals (DuPont, Green Biologics), Polymers (Plaxica), Base Chemicals and Fuels (Koch Industries, Ineos), Food Additives (Biocats), Coatings (Akzo Nobel). This list contain just a few examples from published data, there are a plethora of other examples and case studies. This rapid acceleration of activity and increasingly diverse penetration of these industries provides an unprecedented opportunity.

Impacts UK Chemical Industry

Bulk & Fine Chemicals

2% of GDP 12% of value added in manufacturing £3.5 bilion R&D spend Direct employment: 230,000 > 2,500 SMEs

Pharmaceutical & Biotech

Sales £113 billion

Agrochemicals Coatings & Lubricants

Base Disciplines

Platforms

Chemistry Biology

Synthetic Biology

Home & Personal Care Food & Drink

Chemical Manufacture

Mining

Process Technology

Energy Generation

Engineering

Product Development

Bio-based substitution currently small, huge market opportunities Forecast gain from IB: >£10 billion

Metal Refining Forestry & Paper Construction & Materials Electronics Oil & Gas

Figure 2 Market Potential of IB.

£226 billion

Aerospace & Automotive

£523 billion

07

Industrial Biotechnology Innovation Centre Vision 2030

IBioIC INDUSTRIAL MEMBERSHIP IBioIC is a partnership between Industry and Academia. The Centre will operate an Industrial membership model with three levels of involvement as outlined below.

Leading Members (£50k)

Core Members (£5k)

Associate Members (£0.5k)

• Involvement in Special Interest Groups • Access to all IC reports (except other company contracts) • Access to all networking events • Access to all newsletters and non-confidential publications • Access to Exemplar Programmes • IP access options • 2 x Year review with a Centre Director on specific needs • Seat on IBioIC Board • Optional seat on Commercial Advisory Board • 1 development programme per annum (limited to basic POC – maximum value £50k) • Influencing research and commercial strategy • Access to training programmes – access to skills

• Involvement in Special Interest Groups • Access to all IC reports (except other company contracts) • Access to all networking events • Access to all newsletters and non-confidential publications • Access to exemplar programmes • IP access options • 1 x Year review with a Centre Director on specific needs • One seat on Board across core members • One seat on Commercial Advisory Board across core members • Access to training programmes – access to skills

• Involvement in Special Interest Groups • Access to all IC reports (except other company contracts) • Access to all networking events • Access to all newsletters and non-confidential publications

The success of IBioIC will be evident from the value-add to Members and Associates and resulting economic impact, which in turn will drive the transition to be largely self-funding by Year 5.

“GSK has a business goal to drive manufacture using IB from 2% in 2013 to 20% by 2020” Dr Dave Tudor, Primary Supply Chain Head, GSK

“INEOS Bio is commercializing a revolutionary new process for converting waste biomass into bioethanol and renewable electricity. IBioIC will provide a source of expertise to help us make wise investment decision and to provide a forum for interaction with future partner companies” Dr Ian Little, Ineos PLC

08

IBioIC Industrial Membership

IBioIC INDUSTRIAL MEMBERSHIP IBioIC is already strongly supported by more than 25 companies who use or plan to use IB in their business and have committed a financial contribution to IBioIC. Critical to the success of IBioIC will be its staffing by industry experienced personnel with a deep knowledge of IB and global network of contacts. Also crucial will be its operation as a single portal offering technology, development, management and technology transfer, handling contractual arrangements and project management from low to high TRL for all partners. This operational structure gives IBioIC a distinct advantage over the rest of the UK where in order to access a

Founding Members

Industry Partners Blue

White

Red

Green

Supporters

programme involving multiple colours of IB, industry is required to negotiate with numerous HEIs considerable distance apart. The aim is to make industrial engagement as easy, simple and effective as possible and will be regularly monitored to constantly improve with time. The ambition is to expand the industrial cluster to contain at least 200 companies of all sizes across the full spectrum of chemical and life science business. IBioIC will be led by industry and focus on SME engagement as a priority in addition to both large and fully multinational companies and will harness world class expertise in Scotland’s academic institutions.

09

Industrial Biotechnology Innovation Centre Vision 2030

OPERATIONAL MODEL IBioIC offers an industry led national Centre which will develop a highly attractive, resource leveraging and easy to engage with open innovation mechanism. The industry leadership will ensure strong market pull and the Centre will have the funding and support to recruit the most able team of industrially experienced IB experts providing the best support and project management capability for company partners. IBioIC will be targeting a balanced mix of companies and expects to run both multi-company and company specific projects.

The operational strategy is for the IBioIC to operate within the Technology Readiness model levels 2 to 7 (Figure 3), i.e. primary research on business issues, research application, and then develop the technology through to small pilot scale technical demonstration, to produce robust technical transfer packages that can be scaled up in the companies themselves or working in concert with the TSB High Value Manufacturing Catapult and CPI to fully demonstrate commercial viability.

It is very important to differentiate the IBioIC as a centre which will use technology and innovation from academia to drive forward solutions to industrial problems and for business need.

Figure 3 An illustration of how IBioIC transforms low TRL technologies into high TRL outcomes.

10

Operational Model

OPERATIONAL MODEL Figure 4 shows the breadth of activities that IBioIC will undertake – from funded programmes, studentships and secondments; fee-for-service work; consultancy; providing access to facilities and equipment to outreach and skills and training. The range of stakeholders we will engage with in order to enhance these activities includes industry; EU and UK funding bodies; collaborative centres; professional groups and the public as well as providing the next generation of IB-skilled practitioners.

Figure 4 An illustration of the breadth of activities IBIC will undertake and the range of stakeholders with which IBIC will interact.

COMMERCIALISATION

OUTREACH

SKILLS & KE

Core-funded programmes Studentships Secondments

Professional Forums

Next generation of IBskilled practitioners

Jointly-funded programmes Studentships Secondments

International Events

Fee-for service programmes Consultancy e.g. TSB, Horizon 2020 and UKRC’s

Public Engagement

International Company Engagement e.g. BBSRC networks, SE, HIE, EPSRC, IBFL, EuropaBio, HEI networks, Catalyst Programmes and Catapults

University Business Schools Collaborative MSc in IB CSS Skills Group, Sector Skills Council etc e.g. Industrial Members, HEI’s, Further Education Institutes, SFC, Cogent and SDS

11

Industrial Biotechnology Innovation Centre Vision 2030

This highly distinctive model gives IBioIC a huge advantage over the rest of the UK where in order to access a programme requiring all these capabilities, industry has to visit numerous geographically distant universities and negotiate with many Technology Transfer Offices (TTOs) just to start a conversation (as illustrated in Figure 5).

Figure 5 An illustration of the distribution and expertise of IB in the UK, demonstrating the unique offering of IBIC.

COLOUR KEY

Health



Marine



Industrial



Agriculture

Newcastle Teesside York

Liverpool

Manchester Nottingham Warwick

Cambridge

Oxford Swansea Cardiff

London Bath

Exeter

12

IBioIC Academic Partners

IBioIC ACADEMIC PARTNERS IBioIC has the commitment of thirteen Scottish HEI partners as shown in Figure 6. This intellectual powerhouse contributes to the encapsulation of all four colours of biotech that is unique in the UK and provides a strong combination of technologies across the complete landscape of IB and the underpinning synthetic and systems biology platforms. Scotland’s HEIs have world-class skills in research areas including feedstock manipulation, systems and synthetic biology, biocatalysis, and applied research in areas directly relevant to the exploitation of IB, such as bioprocessing, biofuels, and waste treatment and upgrading. These institutes have core competences in many organisms used in IB, including algae, yeasts, filamentous fungi, and bacteria ranging from Corynebacterium to Escherichia coli, allowing agility in integrated bioprocess planning. Health

Marine

Industrial

Agriculture

Napier University University of Strathclyde University of Abertay University of St Andrews The James Hutton Institute University of the Highlands and Islands/SAMS University of Glasgow University of Aberdeen University of the West of Scotland

Heriot Watt University University of Edinburgh Robert Gordon University University of Dundee

Figure 6 Scottish HEI partner core competencies.

IBioIC academics have the opportunity to participate in industry-led programmes that will provide funded staff and will be exposed to industry discoveries, ideas and needs that will open up further opportunities for collaborative R&D with industry; provide Pathways to Impact for RCUK grant applications and will provide future Research Excellence Framework Impact case studies. Academics will be encouraged to publish in highimpact journals, whilst being mindful of commercial sensitivities, in order to raise individual and IBioIC profiles. Academics will also be encouraged to initiate innovative projects for which IBioIC will find and select the most appropriate industrial collaborators.

13

Industrial Biotechnology Innovation Centre Vision 2030

IMPLEMENTATION PLAN Phase 1 Discovery and Infrastructure Months 0-18

Phase 2 Deployment Months 18-48

• Recruit Governing Board, IBioIC Management Group and Advisory Boards (Commercial and Scientific) • Establish the rules of Governance for each Board • Establish required infrastructure elements with HEI partners • Select and commence exemplar programmes (details in Appendices 1 & 2 of Implementation Plan attached in Annex 2) • Put in place a collaborative MSc programme in Industrial Biotechnology with content based on industrial need • Develop a PhD programme in Industrial Biotechnology with significant industry input • Establish a HNC programme in Industrial Biotechnology with content based on Industrial need • In consultation with the Industrial membership establish a modern apprenticeship scheme to provide the labour skills required by the Industrial Biotechnology employers • Build and expand the Industrial Membership at all levels • Build external revenue (industry and external funders) • Raise awareness of IB in Scotland’s industries • Develop links with Collaborative Centres and broaden awareness of Scotland’s IB potential internationally

• Further develop the programme portfolio in response to industry demand and using intelligence derived from exemplar programme experience • Extend the external revenue streams • Add new global, large and Scottish SME partners to the consortium • Recruit new academic contributors

Phase 3 Growing a sustainable Centre Months 24-60 • Delivery of high-quality, industry-led programmes • Centre increasingly funded by industry and external funders (40% plus) • Moving towards a sustainable model (similar to the Fraunhofer model) where public core funding is balanced against industrial investment and collaborative research & development funding over the long term.

14

Delivery Programs, Studentships & Consultancy

DELIVERY PROGRAMS, STUDENTSHIPS & CONSULTANCY Following extensive consultation with industry partners, IBioIC Key Delivery Mechanisms will be: 1. Core-funded programmes (including exemplars) identified by industry partners; recommended by Commercial Advisory Board and approved by the Governing Board 2. Jointly-funded programmes with an industry partner(s), the Innovation Centre and external funding bodies such as the UKRCs, TSB or Horizon 2020 3. Fee-for-Service programmes 4. Core-funded studentships, where students spend 3-6 months per year in industry 5. Jointly-funded studentships, where students are based with industry partner 6. Staff secondments – industry to academia and vice versa 7. Consultancy Where programmes require expertise from outside the IBioIC partners, IBioIC will secure that expertise by putting in place appropriate contractual arrangements.

Exemplar programmes The core-funded programmes will initially be delivered through an Exemplar Programme with the following expectations: • To confirm that the IBioIC model works in relation to driving through market led Industrial Biotechnology innovation to appropriate timelines and quality • To prove IBioIC works as a one stop shop in relation to bringing industry and academia together • To complete at least 2 exemplars projects within 12 months from core funding to raise awareness and credibility with our stakeholders but especially industry • To encourage industry to fund future projects i.e. outside of the core funding because we can demonstrate tangible commercial benefits All exemplar projects must be able to demonstrate that there is a clear market need that potentially could be met by the use of innovative Industrial Biotechnology. The project has to include at least two of IBioIC’s HEI Collaboration Partners and one of IBioIC industry members. Once the Exemplar Programme is working successfully, this model will be replicated and rolled out to become the research and development program for the Centre in the subsequent years.

15

Industrial Biotechnology Innovation Centre Vision 2030

FUNDING AND EXPENDITURE CONSULTANCY In total £46.1M of investment is expected to be raised over the first five years, taking Scotland to a forefront position in IB internationally. IBioIC has secured £10M commitment from the Scottish Funding Council (SFC) to help bring about this process of transformative change. Requests for further investment from SFC will be made for skills development and investment in capital infrastructure. IBioIC will leverage other research funding available from RCUK, Horizon 2020, TSB and others.

External funding agencies will include bodies such as TSB, BBSRC, EPSRC and Horizon 2020. Approximately 5% of €70 billion Horizon 2020 fund is IB related, giving IBioIC the potential to access to significant research income for Scottish companies.

IBioIC will have four main investment streams:

The graphs below contains a summary of the planned funding and expenditure of IBioIC.

IBioIC’s focus will be on the delivery of the research and development program, accounting for 66% of total funds over the five year period.

£k

• SFC funding • Cash and in kind industrial membership contributions • In kind investment from the HEI partner base • Support from external funding agencies

10 year funding model

10 Year Expenditure Model

20,000

20000

18,000

18000

16,000

16000

14,000

14000

12,000

12000

10,000

10000

8,000

8000

6,000

6000

4,000

4000

2,000

2000 0

0 2013 2014

2015 2016 2017 2018 2019 2020 2021 2022 2023

n HEI Fund n Collaborative Fund n Industry Fund n SFC Skills Fund n SFC Core Fund

2013 2014

2015 2016 2017 2018 2019 2020 2021 2022 2023

n Projects n Skills Program n Industry Engagement n Management

16

Impact

IMPACT It is forecast that IBioIC will create nearly 1,500 Full Time Equivalent high quality jobs and £128M of Gross Value Added within its first 5 years of operation. These impacts will be generated by direct benefits from the operation of IBioIC, i.e. spend and increased employment; benefits received by SMEs through their interaction with IBioIC, increased revenue, participation in industry-led programmes, training of employees and staff secondments; similar benefits to Scottish-based non-SMEs and multiplier effects from the indirect and induced effects from these increases in economic activity.

ADDITIONAL JOBS CREATED BY IBIC (FULL-TIME EQUIVALENTS) Jobs (Full Time Equivalents) Created

2013

2014

2015

2016

2017

TOTAL

Direct Activity of IBIC project

13

1

7

9.5

11

42

Benefit to SMEs



18

29

46

56

149

Benefit to Non-SMEs



52

127

176

218

573

Total FTEs Created

13

71.5

163

231.5

285

764

Total FTEs created including Multiplier

25

136

312

442

543

1459

Over the longer term IBioIC’s impact on the economy will continue to accelerate with £1.7billion of cumulative GVA impact up to 2025 based on a 60% GVA to sales value ratio.

Annual GVA contribution to Scottish Economy 600 Seeding Period

Growth Period

500

£ millions

400 300 200 100 0 2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Industrial Biotechnology Innovation Centre Vision 2030

17

SKILLS AND KNOWLEDGE OUTPUT IBioIC will be pivotal in creating the next generation of IB-skilled practitioners. In order to do this we will develop an IB Skills & Knowledge Exchange Plan in consultation with Skills Development Scotland, the Chemical Sciences Scotland Skills Group, Life Sciences Scotland Skills Group, relevant Engineering Groups, the Sector Skills Councils, Interface and National Skills Academy for the Process Industries, to ensure a robust Training Needs Analysis is completed and appropriate programmes developed to deliver the required solutions. Examples of Skills & KE activity include: • Core-funded students seconded to industry labs to gain relevant technical & commercial skills • Partner company staff to have one or more academic supervisors to advise on obtaining a higher degree • A Collaborative M.Sc. in Industrial Biotechnology will be delivered by the academic members of the IBioIC consortium in response to industry need • A Collaborative two year HND in Industrial Biotechnology will be delivered by Higher Education Colleges in response to Industry need. Students with good enough grades can enter year 2 of a degree program

• It is intended to build on the success of the ETP in establishing, with the support of the Industrial Membership, IB based modern apprenticeships and corresponding relevant SVQ’s • IBioIC will organize regular meetings for its members, associates and the public, with presentations on topics of general interest, including those given by invited international leaders • IBioIC will also organize international conferences on IB and will establish an outreach programme for academic and industry professionals, including organizing visits to Scotland from potential customers and the IB supply chain, supported by Scottish Development International.

18

Leadership, Management & Governance

LEADERSHIP, MANAGEMENT & GOVERNANCE IBioIC leadership, management & governance have been designed to create an effective partnership between industry and academia which is sustainable and offers an effective voice to all partners. Details of each of the Governance Boards are given below. All the positions on these boards have a two year tenure. LEADERSHIP, MANAGEMENT & GOVERNANCE STRUCTURE Group

Membership

Role

Governing Board

Industrial Chair, CEO, Leading Members, Core Membership Representative, Senior Officers (2 HEI’s in rotation), SFC,SE & HIE Observers

Governs IBioIC activities and sets the strategic and commercial direction. Responsible for compliance, financial oversight and risk management.

Commercial Advisory Board (CAB)

CEO, 4 Industry Members (2 from SMEs and 2 from Large Companies), 2 HEI Members, SE/HIE Observers

Reports to the Governing Board. Runs the project competitions. Guide the Centre on maximizing the commercial impact of IBioIC and enhancing the Industrial reputation of IBioIC.

Scientific Advisory Board (SAB)

CEO, Industrial Members, 4 HEI members plus up to 2 Internationally recognized academics, SE/HIE observers

Reports to the Governing Board. Oversee the projects, advise the Centre on technical issues and capital spend, promote the technical excellence of IBioIC and advise the CAB on the technical merit of the project competition entries.

IBioIC Management Team

CEO, Programme & IPR Managers TechnoCommercial BD and Project Managers, Communications & Marketing Officer and HEI leads

Management of IBioIC activities

THE INITIAL PARTICIPANTS OF THE GOVERNING BOARD ARE: Members:

Ian Shott CBE, FREng – Independant Chair Roger Kilburn – IBioIC CEO Dr Ian Fotheringham – CEO Ingenza (Industrial) Dr Ian Little – R&D Manager, Ineos Technologies (Industrial) Dave Tudor – VP Primary Supply Chain, GSK (Industrial) Dr Sandy Dobbie – Director MBL, Chair of CSS (Industrial) Prof Brian McNeil – SIPBS Royal College, University of Strathclyde (HEI) Prof Gary Loake – Institute of Molecular Plant Sciences, University of Edinburgh (HEI) Observers:

Keith McDonald – Senior Policy Officer, Scottish Funding Council Caroline Strain – Head of Chemical Sciences, Scottish Enterprise James Cameron – Head of Life Sciences, Highlands and Islands Enterprise

Industrial Biotechnology Innovation Centre Vision 2030

19

20

Conclusions

CONCLUSIONS IBioIC will be a Centre guided by Business for Business and will facilitate, de-risk and accelerate the exploitation of novel technology in the pursuit of better solutions for the reality of the business marketplace. IBioIC will hire the best talent to maintain a highly effective expert team to add real value to all opportunities, challenges and targeted projects and provide a truly distinctive and needed service to business. IBioIC will confront and propose solutions to any issues that hamper open innovation, technology transfer and ultimate commercialisation. IBioIC will ensure that its IP policies provide a secure environment that protects collaborators but at the same time are flexible enough to promote and actively encourage exploitation in an efficient and effective manner. IBioIC will always seek to leverage the commitment of business several-fold by harnessing the IB network of knowledge and resource support by substantial funding from RCUK, TSB and EU sources for collaborative and company-specific projects. IBioIC will collaborate with the TSB High Value Manufacturing Catapult, CPI and other Innovation Clusters to fully leverage all existing assets and will not needlessly compete with existing publicly funded offerings wherever they reside.

IBioIC represents an exciting opportunity for business, academia and government to continue the development of a truly sustainable and balanced growth economy in Scotland.

Acknowledgements The IBioIC Governing Board wish to thank Mr Kevin Moore and Prof. Iain Hunter for their services on the Interim Board, additionally the team at Strathclyde University who all made a substantial contribution in successfully securing the seed funding from the SFC. Prepared by: Industrial Biotechnology Innovation Centre (IBioIC) On behalf of: The IBioIC Governing Board The Scottish Funding Council (SFC) Highlands & Islands Enterprise (HIE) Scottish Enterprise (SE) Chemistry Innovation Knowledge Transfer Network (CIKTN) Biosciences Knowledge Transfer Network (BKTN) Chemical Sciences Scotland (CSS) For further information, please contact: Roger Kilburn [email protected] +44 (0)141 548 4759

Suggest Documents